Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Blackfinch Investments (Fund)
Blackfinch Ventures EIS Portfolios
2nd Dec 2024
Calculus Capital (Funds)
Calculus Knowledge Intensive EIS Fund 3
29th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
108: An all-star panel discuss EIS & VCTs in 2024 and look forward to 2025
Stay up-to-date with the latest research
Sign up to our newsletter
Latest Update
Our research can be accessed for free under MIFID.
Find out more >
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Infrastructure
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Transportation
Utilities
list companies
Burford Capital
Financials
Fund business shows good progress
By
Dr Brian Moretta
15 Dec 2017
ValiRx
Life Sciences
Clinical efficacy of VAL401
13 Dec 2017
Stay up-to-date with the latest research
Sign up to our newsletter
Evgen Pharma
Life Sciences
Funded to the end of Phase II trials
By
Dr Martin Hall
11 Dec 2017
Advanced Oncotherapy
Life Sciences
Distribution agreement and capital increase
By
Dr Martin Hall
11 Dec 2017
Chamberlin Plc
Industrial
Continued technical issues lead to lower forecasts
By
Paul Singer
29 Nov 2017
Primary Health Properties
Investment Companies
Gilt edged rent collector – accelerating dividends
By
Mike Foster
23 Nov 2017
Redx Pharma
Life Sciences
Streamlined and clean
By
Dr Martin Hall
13 Nov 2017
Chamberlin Plc
Industrial
One-off cost inefficiencies lead to lower forecasts
By
Paul Singer
18 Oct 2017
Alliance Pharma Plc
Life Sciences
Kelo-cote building international sales
By
Dr Martin Hall
17 Oct 2017
Avacta Group plc
Life Sciences
R&D accelerated to advance assets
By
Dr Martin Hall
16 Oct 2017
Tissue Regenix
Life Sciences
Dual revenue stream growth
11 Oct 2017
Prev
1
...
23
24
25
26
27
...
30
Next
